Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 19 May 2016 - Galapagos NV (Euronext & NASDAQ: GLPG)
announces a share capital increase arising from warrant exercises.
Galapagos issued 140,770 new ordinary shares on 19 May 2016, for a total capital
increase (including issuance premium) of ?1,476,401.70.
CEO Onno van de Stolpe exercised 90,000 warrants that were due to expire this
month for a total of ?895,500 and has held the resulting shares. He consequently
increased his holding to a total of 628,289 Galapagos shares. In addition to
Onno van de Stolpe, one other Board member exercised 7,500 warrants. Moreover,
pursuant to the warrant exercise program of Galapagos' Executive Committee,
Executive Committee members automatically are committed to exercise a minimum
number of warrants, subject to certain conditions. Pursuant to the rules of this
program, two Executive Committee members exercised an aggregate number of 5,000
warrants, also to hold as shares.
In accordance with Belgian transparency legislation[1], Galapagos notes that its
total share capital currently amounts to ?249,394,222.78; the total number of
securities conferring voting rights is 46,109,508, which is also the total
number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 2,981,227, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos(Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1, pre-
clinical and discovery studies in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 440 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Director Communications
Communications +31 6 53 591 999
+1 781 460 1784 communications(at)glpg.com
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "anticipates," "believes,"
"continues," "could," "estimates," "expects," "intends," "may," "plans,"
"seeks," "stands to," "we believe," "will," "we intend," as well as similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results, financial
condition and liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements expressed or
implied by such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the development of
the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements (including
that data from Galapagos' ongoing clinical research programs may not support
registration or further development of its product candidates due to safety,
efficacy or other reasons), Galapagos' reliance on collaborations with third
parties, and estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' most recent annual report on form
20-F filed with the SEC and subsequent filings and reports filed by Galapagos
with the SEC. Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such forward-looking statements
in this document to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such statement
is based or that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless specifically required
by law or regulation.
--------------------------------------------------------------------------------
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market
GLPG increases share capital through warrant exercises:
http://hugin.info/133350/R/2014102/746612.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#2014102]
Unternehmensinformation / Kurzprofil:
Datum: 19.05.2016 - 22:16 Uhr
Sprache: Deutsch
News-ID 472528
Anzahl Zeichen: 7038
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
